105297-10-7 Usage
General Description
4-(4-Aminophenyl)thiomorpholine 1,1-dioxide is a chemical compound with a complex structural formula, indicating its composition as a derivative of thiomorpholine of the sulfonamide class. Its structure features a four-membered heterocyclic ring, phenyl ring and complex functional groups, which may play a significant role in its chemical reactivity, stability, and bioactivity. This chemical compound can be used in various scientific research and industrial applications, including as an intermediate in the pharmaceutical sector and in the synthesis of more complex chemical compounds. The safety, hazard and environmental impact associated with this chemical would depend on various factors such as its handling, concentration, location of use, among others. The complete risk assessment depends on more specific information and should be based on comprehensive data and regulatory guidelines.
Check Digit Verification of cas no
The CAS Registry Mumber 105297-10-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,5,2,9 and 7 respectively; the second part has 2 digits, 1 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 105297-10:
(8*1)+(7*0)+(6*5)+(5*2)+(4*9)+(3*7)+(2*1)+(1*0)=107
107 % 10 = 7
So 105297-10-7 is a valid CAS Registry Number.
InChI:InChI=1/C10H14N2O2S/c11-9-1-3-10(4-2-9)12-5-7-15(13,14)8-6-12/h1-4H,5-8,11H2
105297-10-7Relevant articles and documents
COMPOUNDS AND THEIR USES AS SPLEEN TYROSINE KINASE INHIBITORS
-
Paragraph 0100, (2021/12/28)
Provided are compounds of Formula (I) which can be used as Syk inhibitors and potently as therapeutic agents against diseases mediated by Syk.
2, 4 -DIAMINOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS
-
Page/Page column 110, (2012/05/20)
The present invention relates to novel pyrimide derivatives of formula (I): that are useful as kinase inhibitors. More particularly, the present invention relates to novel pyrimidine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders.
